Drug Trial Radar · NCT07007559
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 10, 2025
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- ALX Oncology Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer who have previously received trastuzumab-deruxtecan. This substudy is actively recruiting. ASPEN-09-03 is a substudy under Master Protocol ASPEN-09, and additional substudies are as follows: * Metastatic colorectal cancer (CRC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open. * Recurrent/metastatic head and neck cancer (HNSCC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open.
Conditions
- Breast Cancer, Metastatic
Interventions
Evorpacept (ALX148)Drug
IV infusion
TrastuzumabDrug
IV infusion
PaclitaxelDrug
IV infusion
CapecitabineDrug
Oral administration
EribulinDrug
IV infusion
GemcitabineDrug
IV infusion
VinorelbineDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessmentTime frame: Approximately 6 months after the last participant is enrolled
Locations
61 sites in 8 countries. Site status is shown where the registry gives one.
Mayo Clinic Building-Phoenix
Phoenix, Arizona · Recruiting
The University of Arizona Cancer Center - North Campus
Tucson, Arizona · Recruiting
City of Hope
Duarte, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Saint Joseph Hospital - Cancer Centers of Colorado
Denver, Colorado · Withdrawn
Lutheran Hospital - Cancer Centers of Colorado
Golden, Colorado · Recruiting
Saint Mary's Regional Hospital - Cancer Centers of Colorado
Grand Junction, Colorado · Recruiting
The George Washington Medical facility Associates
Washington D.C., District of Columbia · Recruiting
Mayo Clinic
Jacksonville, Florida · Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
City of Hope Chicago
Zion, Illinois · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Mayo Clinic Cancer Center
Rochester, Minnesota · Recruiting
HealthPartners Frauenshuh Cancer Center
Saint Louis Park, Minnesota · Recruiting
Washington University School of Medicine- Siteman Cancer Center
St Louis, Missouri · Recruiting
St. Vincent Regional Hospital - Cancer Centers of Montana
Billings, Montana · Recruiting
Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Houston Methodist Cancer Center
Houston, Texas · Recruiting
The University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
CHU de Besancon
Besançon, France · Recruiting
Institut Bergonie
Bordeaux, France · Recruiting
Hopital de l'Institut Curie
Paris, France · Recruiting
Hopital Europeen Georges Pompidou (HEGP)
Paris, France · Recruiting
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, France · Recruiting
Centre Eugene Marquis
Rennes, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
ASST Papa Giovanni XXIII
Bergamo, Italy · Recruiting
IRCCS Azienda Ospedaliero- Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna, Italy · Recruiting
IRCCS- Istituto Europeo di Oncologia
Milan, Italy · Recruiting
Fondazione IRCCS San Gerardo Dei Tintori
Monza, Italy · Recruiting
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.